Titanovo Logo
Back to Cell Types

LoVoHomo sapiens (Human)Cancer cell line

Also known as: LOVO

🤖 AI SummaryBased on 13 publications

Quick Overview

Human colorectal cancer cell line with diverse molecular characteristics.

Detailed Summary

LoVo is a human colorectal cancer cell line derived from a colon adenocarcinoma. It is widely used in cancer research due to its distinct molecular features and ability to model various aspects of colorectal cancer biology. The cell line exhibits specific genetic and epigenetic alterations that make it a valuable tool for studying tumor progression, drug resistance, and therapeutic responses. Its use in preclinical studies helps in understanding the mechanisms underlying cancer development and in developing targeted therapies.

Research Applications

Cancer biology researchDrug developmentMolecular mechanisms of tumor progressionTherapeutic response studies

Key Characteristics

Genomic instabilityEpigenetic alterationsExpression of specific oncogenes
Generated on 6/15/2025

Basic Information

Database IDCVCL_0399
SpeciesHomo sapiens (Human)
Tissue SourceLeft supraclavicular lymph node[UBERON:UBERON_8480056]

Donor Information

Age56
Age CategoryAdult
SexMale
Racecaucasian
Subtype FeaturesMSI

Disease Information

DiseaseColon adenocarcinoma
LineageBowel
SubtypeColon Adenocarcinoma
OncoTree CodeCOAD

DepMap Information

Source TypeATCC
Source IDACH-000950_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleACVR2Ap.Lys437Argfs*5 (c.1310delA)Homozygous-PubMed=12615714
MutationSimpleAPCp.Arg1114Ter (c.3340C>T)Heterozygous-from parent cell line LoVo
MutationSimpleAPCp.Met1431fs*42 (c.4289delC) (p.T1430fs)Heterozygous-from parent cell line LoVo
MutationSimpleAPCp.Arg2816Gln (c.8447G>A)Heterozygous-from parent cell line LoVo
MutationSimpleB2Mp.Leu15Phefs*41 (c.43_44delCT)HeterozygousTotal loss of HLA class 1 expressionfrom parent cell line LoVo
MutationSimpleFBXW7p.Arg505Cys (c.1513C>T)Heterozygous-from parent cell line Jurkat
MutationSimpleKRASp.Gly13Asp (c.38G>A)HeterozygousSomaticfrom parent cell line MDA-MB-231
MutationSimpleSMAD2p.Ala292Val (c.875C>T)Heterozygous-from parent cell line LoVo
MutationSimpleTGFBR2p.Lys128Serfs*35 (c.383delA)Homozygous-PubMed=12615714
MutationNone reportedTP53---PubMed=19787792

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X,Y
CSF1PO
10,11,13,14
D13S317
8,11
D16S539
9,11,12
D18S51
13,17,18
D19S433
14,15
D21S11
29,31.2
D2S1338
16,17,18
D3S1358
14,15,16,17
D5S818
11,12,13
D7S820
9.3,10,11
D8S1179
9,10
FGA
18,19,20
Penta D
9,10,14
Penta E
9,16
SE33
19.2,20.2,25.2
TH01
9.3
TPOX
8,9
vWA
16,17,18,19
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

DOIPubMedPMC

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

DOIPubMedPMC

The cancer SENESCopedia: a delineation of cancer cell senescence.";

Leite de Oliveira R., Wessels L.F.A., Bernards R.

Cell Rep. 36:109441.1-109441.22(2021).

DOIPubMedPMC

Comparison of different colorectal cancer with liver metastases models using six colorectal cancer cell lines.

Xu Y.-T., Zhang L., Wang Q.-L., Zheng M.-J.

Pathol. Oncol. Res. 26:2177-2183(2020).

DOIPubMed

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

DOIPubMedPMC

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Nature 568:511-516(2019).

DOIPubMed

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

DOIPubMedPMC

Differential effector engagement by oncogenic KRAS.";

McCormick F.

Cell Rep. 22:1889-1902(2018).

DOIPubMedPMC

Pharmacoproteomic characterisation of human colon and rectal cancer.

Weichert W., Knapp S., Feller S.M., Kuster B.

Mol. Syst. Biol. 13:951-951(2017).

DOIPubMedPMC

Genomic determinants of protein abundance variation in colorectal cancer cells.

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Choudhary J.S.

Cell Rep. 20:2201-2214(2017).

DOIPubMedPMC

Multi-omics of 34 colorectal cancer cell lines -- a resource for biomedical studies.

Myklebost O., Skotheim R.I., Sveen A., Lothe R.A.

Mol. Cancer 16:116.1-116.16(2017).

DOIPubMedPMC

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

DOIPubMedPMC

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

DOIPubMedPMC

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

DOIPubMedPMC

N-glycosylation profiling of colorectal cancer cell lines reveals association of fucosylation with differentiation and caudal type homebox 1 (CDX1)/villin mRNA expression.

Tollenaar R.A.E.M., Rombouts Y., Wuhrer M.

Mol. Cell. Proteomics 15:124-140(2016).

DOIPubMedPMC

Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.

Golub T.R., Root D.E., Hahn W.C.

Sci. Data 1:140035-140035(2014).

DOIPubMedPMC

Highly expressed genes in rapidly proliferating tumor cells as new targets for colorectal cancer treatment.

Sanchez A., Schwartz S. Jr., Bilic J., Mariadason J.M., Arango D.

Clin. Cancer Res. 21:3695-3704(2015).

DOIPubMed

The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets.

Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.

Nat. Commun. 6:7002.1-7002.10(2015).

DOIPubMed

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

DOIPubMed

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

DOIPubMed

Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.

Mariadason J.M., Sieber O.M.

Cancer Res. 74:3238-3247(2014).

DOIPubMed

Epigenetic and genetic features of 24 colon cancer cell lines.";

Hektoen M., Lind G.E., Lothe R.A.

Oncogenesis 2:e71.1-e71.8(2013).

DOIPubMedPMC

Establishment of a human carcinoembryonic antigen-producing colon adenocarcinoma cell line.

Drewinko B., Romsdahl M.M., Yang L.-Y., Ahearn M.J., Trujillo J.M.

Cancer Res. 36:467-475(1976).

PubMed

Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.

Cancer Res. 48:589-601(1988).

PubMed

Karyotype consistency in human colorectal carcinoma cell lines established in vitro.

Chen T.-R., Hay R.J., Macy M.L.

Cancer Genet. Cytogenet. 6:93-117(1982).

DOIPubMed

Increased incidence of p53 mutations is associated with hepatic metastasis in colorectal neoplastic progression.

Steele G., Summerhayes I.C.

Oncogene 11:647-652(1995).

PubMed

Beta 2-microglobulin gene mutations: a study of established colorectal cell lines and fresh tumors.

Bicknell D.C., Rowan A.J., Bodmer W.F.

Proc. Natl. Acad. Sci. U.S.A. 91:4751-4755(1994).

DOIPubMedPMC

Tissue typing the HLA-A locus from genomic DNA by sequence-specific PCR: comparison of HLA genotype and surface expression on colorectal tumor cell lines.

Bodmer W.F.

Proc. Natl. Acad. Sci. U.S.A. 90:2842-2845(1993).

DOIPubMedPMC

Inverse correlation between RER+ status and p53 mutation in colorectal cancer cell lines.

Thomas G., Hamelin R.

Oncogene 13:2727-2730(1996).

PubMed

BAT-26, an indicator of the replication error phenotype in colorectal cancers and cell lines.

Hamelin R.

Cancer Res. 57:300-303(1997).

PubMed

Screening the p53 status of human cell lines using a yeast functional assay.

Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.

Mol. Carcinog. 19:243-253(1997).

DOIPubMed

Beta-catenin mutations in cell lines established from human colorectal cancers.

Ilyas M., Tomlinson I.P.M., Rowan A.J., Pignatelli M., Bodmer W.F.

Proc. Natl. Acad. Sci. U.S.A. 94:10330-10334(1997).

DOIPubMedPMC

Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer.

Sparks A.B., Morin P.J., Vogelstein B., Kinzler K.W.

Cancer Res. 58:1130-1134(1998).

PubMed

Chromosome number and structure both are markedly stable in RER colorectal cancers and are not destabilized by mutation of p53.

Veigl M.L., Willson J.K.V., Schwartz S., Markowitz S.D.

Oncogene 17:719-725(1998).

DOIPubMed

Centrosome amplification and instability occurs exclusively in aneuploid, but not in diploid colorectal cancer cell lines, and correlates with numerical chromosomal aberrations.

Neumann T., Jauho A., Auer G., Ried T.

Genes Chromosomes Cancer 27:183-190(2000).

DOIPubMedPMC

Mutations in hMSH6 alone are not sufficient to cause the microsatellite instability in colorectal cancer cell lines.

Ku J.-L., Yoon K.-A., Kim D.-Y., Park J.-G.

Eur. J. Cancer 35:1724-1729(1999).

DOIPubMed

APC mutations in sporadic colorectal tumors: a mutational 'hotspot' and interdependence of the 'two hits'.

Papadopoulou A., Bicknell D.C., Bodmer W.F., Tomlinson I.P.M.

Proc. Natl. Acad. Sci. U.S.A. 97:3352-3357(2000).

DOIPubMedPMC

Spectral karyotyping suggests additional subsets of colorectal cancers characterized by pattern of chromosome rearrangement.

Bicknell D.C., Bodmer W.F., Arends M.J., Wyllie A.H., Edwards P.A.W.

Proc. Natl. Acad. Sci. U.S.A. 98:2538-2543(2001).

DOIPubMedPMC

Searching for microsatellite mutations in coding regions in lung, breast, ovarian and colorectal cancers.

Minna J.D.

Oncogene 20:1005-1009(2001).

DOIPubMed

Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures.

Wolf E., Gabius H.-J.

J. Cancer Res. Clin. Oncol. 127:375-386(2001).

DOIPubMed

Short tandem repeat profiling provides an international reference standard for human cell lines.

Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.

Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001).

DOIPubMedPMC

Extensive characterization of genetic alterations in a series of human colorectal cancer cell lines.

Hamelin R.

Oncogene 20:5025-5032(2001).

DOIPubMed

Immunocytochemical analysis of cell lines derived from solid tumors.

Quentmeier H., Osborn M., Reinhardt J., Zaborski M., Drexler H.G.

J. Histochem. Cytochem. 49:1369-1378(2001).

DOIPubMed

Mutations of the BRAF gene in human cancer.";

Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.

Nature 417:949-954(2002).

DOIPubMed

Spectral karyotype analysis of colon cancer cell lines of the tumor suppressor and mutator pathway.

Koehrle J., Al-Taie O.

Cytogenet. Genome Res. 98:22-28(2002).

DOIPubMed

Evidence of selection for clones having genetic inactivation of the activin A type II receptor (ACVR2) gene in gastrointestinal cancers.

Willson J.K.V., Yeo C.J., Hruban R.H., Kern S.E.

Cancer Res. 63:994-999(2003).

PubMed

Identification of microsatellite instability and mismatch repair gene mutations in breast cancer cell lines.

Santibanez-Koref M.F., Schlag P.M., Scherneck S.

Genes Chromosomes Cancer 37:29-35(2003).

DOIPubMed

SKY and genetic fingerprinting reveal a cross-contamination of the putative normal colon epithelial cell line NCOL-1.

Kudlich T., Schauber J., Luehrs H., Menzel T., Scheppach W.

Cancer Genet. Cytogenet. 158:84-87(2005).

DOIPubMed

p53-defective tumors with a functional apoptosome-mediated pathway: a new therapeutic target.

Tomoda H., Yamori T., Tsuruo T.

J. Natl. Cancer Inst. 97:765-777(2005).

DOIPubMed

Analysis of p53 mutations and their expression in 56 colorectal cancer cell lines.

Liu Y., Bodmer W.F.

Proc. Natl. Acad. Sci. U.S.A. 103:976-981(2006).

DOIPubMedPMC

Identification by real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues.

Garcia-Foncillas J.

Mol. Cancer 5:29.1-29.10(2006).

DOIPubMedPMC

Cell growth, global phosphotyrosine elevation, and c-Met phosphorylation through Src family kinases in colorectal cancer cells.

Emaduddin M., Bicknell D.C., Bodmer W.F., Feller S.M.

Proc. Natl. Acad. Sci. U.S.A. 105:2358-2362(2008).

DOIPubMedPMC

Definitive molecular cytogenetic characterization of 15 colorectal cancer cell lines.

Camps J., McNeil N.E., Difilippantonio M.J., Ried T.

Genes Chromosomes Cancer 49:204-223(2010).

DOIPubMedPMC

Rapid characterisation of cell cultures by matrix-assisted laser desorption/ionisation mass spectrometric typing.

Karger A., Bettin B., Lenk M., Mettenleiter T.C.

J. Virol. Methods 164:116-121(2010).

DOIPubMed

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

DOIPubMedPMC

Genomic and biological characterization of exon 4 KRAS mutations in human cancer.

Lash A., Ladanyi M., Saltz L.B., Heguy A., Paty P.B., Solit D.B.

Cancer Res. 70:5901-5911(2010).

DOIPubMedPMC

5-fluorouracil response in a large panel of colorectal cancer cell lines is associated with mismatch repair deficiency.

Bracht K., Nicholls A.M., Liu Y., Bodmer W.F.

Br. J. Cancer 103:340-346(2010).

DOIPubMedPMC

Human embryonic stem cells and metastatic colorectal cancer cells shared the common endogenous human microRNA-26b.

Peng J.-Y., Chen H.-Q., Zhou Y.-K., Liu W.-J., Qin H.-L.

J. Cell. Mol. Med. 15:1941-1954(2011).

DOIPubMedPMC

Web Resources

cellosaurus.orgsynapse.orgthermofisher.comtcpaportal.org